Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
309 Leser
Artikel bewerten:
(1)

PRODUCTLIFE GROUP ACQUIRES RNI, EXPANDING ITS SCIENTIFIC AND REGULATORY OFFERING TO SELFCARE PRODUCTS

Finanznachrichten News

ProductLife Group, a global provider of regulatory and compliance services for the life sciences industry, strengthens its regulatory expertise in borderline products with the acquisition of RNI, a consulting firm providing global regulatory and scientific services across the entire spectrum of Nutrition and Consumer Healthcare products.

PARIS, July 20, 2023 /PRNewswire/ -- ProductLife Group (PLG), the global and specialized provider of regulatory, scientific, vigilance and quality services for the life sciences industries, announces the acquisition of RNI, an expert consultancy providing support in regulatory, medical and scientific affairs for nutrition and health products, with presence in France, the US and the UK.

Co-founded in 2006 by Violaine Chaumont, RNI delivers a comprehensive scope of regulatory services, including development strategy, scientific and toxicology expertise, due diligence work and quality audits. With an international understanding of regulations, RNI's team supports and advises nutraceutical, cosmetics, pharmaceutical, medical devices, active ingredient, and food companies to reach full market approval for their products. The company benefits from a unique regulatory and case law database and close partnerships with specialized trade federations.

Violaine Chaumont, Chief Executive Officer of RNI, said, "Since our foundation, we have set out to bring expert knowledge to support product development, registration and compliance and help manufacturers and brand-owners to navigate through all regulations applicable to selfcare products. By joining PLG, we will add the resources, international profile and expanded client base we need to take our business to the next level".

Xavier Duburcq, Chief Executive Officer of PLG, said, "Thanks to RNI's recognized regulatory expertise, we will be able to deliver an even greater value to clients, helping them navigate through an increasingly challenging market, where product regulatory classifications are becoming even more blurred. The complementary skills and offerings of our respective operations will truly be synergistic in serving our existing clients while increasing our client base. We are confident the RNI team will further enhance our ability to capture the growing customer demand for services to market safe and healthy products, globally".

About ProductLife Group:

ProductLife Group's mission is to improve human health by delivering regulatory & compliance services for the safe and effective use of medical solutions. PLG supports clients through the entire product life cycle, combining local expertise with global reach spanning more than 150 countries. It provides consulting and outsourcing services in the areas of product development, regulatory affairs, quality management and compliance, vigilance and medical information, covering both established products and innovative therapeutics & diagnostics.

With a goal of continuously improving the value delivered to people and customers, PLG is committed to long-term partnership, innovation, flexibility, and cost efficiency.

For more information, visit https://productlifegroup.com/

RNI

Co-founded in France by Violaine Chaumont in 2006, RNI offers cutting-edge expertise in regulatory, medical and scientific affairs for nutrition and health products. RNI bridges the gap between countries, supporting clients in achieving their domestic and international goals. RNI has expanded its coverage by opening offices in the United States in 2015 and the United Kingdom in 2019. The firm also has a strong network of local partners in Asia, Latin America and the Middle East.

RNI's objective is and will always be the same: thinking beyond mere compliance, addressing developments and projects, even the most complex ones, in a bold and strategic way.

For more information, visit https://www.rni-consulting.com/

Cision View original content:https://www.prnewswire.co.uk/news-releases/productlife-group-acquires-rni-expanding-its-scientific-and-regulatory-offering-to-selfcare-products-301881507.html

© 2023 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.